Molecular pathology of non-invasive urothelial carcinomas (part I)

被引:29
作者
Helpap, B [1 ]
Schmitz-Dräger, BJ
Hamilton, PW
Muzzonigro, G
Galosi, AB
Kurth, KH
Lubaroff, D
Waters, DJ
Droller, MJ
机构
[1] Hegau Klinikum, Inst Pathol, D-78207 Singen, Germany
[2] Euromed Clin, Dept Urol, D-90763 Furth, Germany
[3] Ctr Hlth Care Informat, Dept Pathol, Belfast, Antrim, North Ireland
[4] Univ Ancona, Azienda Osped Umberto 1, Inst Urol, Ancona, Italy
[5] Univ Amsterdam, Dept Urol, Amsterdam, Netherlands
[6] Univ Iowa, Dept Urol, Iowa City, IA 52242 USA
[7] Gerald P Murphy Canc Fdn, Seattle, WA USA
[8] Mt Sinai Med Ctr, Dept Urol, New York, NY 10029 USA
关键词
papillary bladder cancer; non-invasive; cell proliferation; cytokeratins; tumor suppressor genes;
D O I
10.1007/s00428-002-0748-0
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
An international consultation on the diagnosis of non-invasive urothelial neoplasms was held in Ancona, Italy in May 2001. Besides histology and problems of classification, one group of experts (Committee no. 3) discussed the molecular pathology and cytometry of non-invasive urothelial carcinomas. In the following first part, special immunohistochemical and molecular markers for stratifications in bladder cancer were discussed including different cytokeratins (clone 34betaE12, CK 20), cell proliferation markers (Ki67/MIB-1, PCNA, AgNOR, DNA-cytometry), tumor suppressor genes and oncogenes (p53. p21. erb-132, bcl-2), different receptor expressions of epidermal growth factor and vascular endothelial growth factor and others. These molecular markers were analyzed in diagnosis of urothelial carcinomas, recurrences, progression and response to treatment.
引用
收藏
页码:309 / 316
页数:8
相关论文
共 54 条
[41]  
SchmitzDrager BJ, 1997, EUR UROL, V32, P487
[42]   P53 IMMUNOHISTOCHEMISTRY AS AM INDEPENDENT PROGNOSTIC FACTOR FOR SUPERFICIAL TRANSITIONAL-CELL CARCINOMA OF THE BLADDER [J].
SERTH, J ;
KUCZYK, MA ;
BOKEMEYER, C ;
HERVATIN, C ;
NAFE, R ;
TAN, HK ;
JONAS, U .
BRITISH JOURNAL OF CANCER, 1995, 71 (01) :201-205
[43]  
Sgambato A, 1999, CANCER RES, V59, P3245
[44]   E-cadherin expression predicts clinical outcome in carcinoma in situ of the urinary bladder [J].
Shariat, SF ;
Pahlavan, S ;
Baseman, AG ;
Brown, RM ;
Green, PE ;
Wheeler, TM ;
Lerner, SP .
UROLOGY, 2001, 57 (01) :60-65
[45]   Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer [J].
Stein, JP ;
Ginsberg, DA ;
Grossfeld, GD ;
Chatterjee, SJ ;
Esrig, D ;
Dickinson, MG ;
Groshen, S ;
Taylor, CR ;
Jones, PA ;
Skinner, DG ;
Cote, RJ .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (14) :1072-1079
[46]   Prevalence and clinical significance of HER-2/neu, p53 and rb expression in primary superficial bladder cancer [J].
Tetu, B ;
Fradet, Y ;
Allard, P ;
Veilleux, C ;
Roberge, N ;
Bernard, P .
JOURNAL OF UROLOGY, 1996, 155 (05) :1784-1788
[47]  
Thomsen L L, 1994, Eur J Neurol, V1, P73, DOI 10.1111/j.1468-1331.1994.tb00053.x
[48]   Prognostic significance of p53 protein accumulation in stage pT1 transitional cell carcinoma of the bladder [J].
Toktaş G. ;
Türkeri L.N. ;
Ünlüer E. ;
Atuǧ F. ;
Murat C. ;
Özveren B. ;
Çalişkan M. ;
Akdaş A. .
International Urology and Nephrology, 1999, 31 (4) :437-441
[49]   Numerical aberrations of chromosome 9 in bladder cancer. A possible prognostic marker for early tumor recurrence [J].
Tsukamoto, M ;
Matsuyama, H ;
Oba, K ;
Yoshihiro, S ;
Takahashi, M ;
Naito, K .
CANCER GENETICS AND CYTOGENETICS, 2002, 134 (01) :41-45
[50]  
Tzai TS, 1998, ANTICANCER RES, V18, P4717